Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)

被引：7

作者：

Weidinger, Stephan ^{[1
]}

Blauvelt, Andrew ^{[2
]}

Papp, Kim ^{[3
,4
]}

Reich, Adam ^{[5
]}

Lee, Chih-Hung ^{[6
]}

Worm, Margitta ^{[7
]}

Lynde, Charles ^{[8
]}

Kataoka, Yoko ^{[9
]}

Foley, Peter ^{[10
]}

Weber, Christine ^{[11
]}

Wong, Wanling ^{[12
]}

Hurbin, Fabrice ^{[13
]}

Rynkiewicz, Natalie ^{[14
]}

Yen, Karl ^{[15
]}

Wei, Xiaodan

O'Malley, John T. ^{[16
]}

Bernigaud, Charlotte ^{[11
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Kiel, Germany

[2] Oregon Med Res Ctr, Portland, OR USA

[3] Alliance Clin Trials & Prob Med Res, Waterloo, ON, Canada

[4] Univ Toronto, Toronto, ON, Canada

[5] Univ Rzeszow, Dept Dermatol, Rzeszow, Poland

[6] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan

[7] Univ Med Ctr Berlin, Dept Dermatol & Allergol, Berlin, Germany

[8] Univ Toronto, Markham, ON, Canada

[9] Osaka Habikino Med Ctr, Habikino, Japan

[10] Skin Hlth Inst, Carlton, Vic, Australia

[11] Sanofi, Paris, France

[12] Sanofi, Bridgewater, NJ USA

[13] Sanofi, Montpellier, France

[14] Sanofi, Cambridge, England

[15] Sanofi, Rotkreuz, Switzerland

[16] Sanofi, Cambridge, MA USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷

关键词：

monoclonal antibody; anti-OX40L; phase; 2b; biologic therapy; dose-ranging;

D O I：

10.1093/bjd/ljad498.028

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

523

引用

页码：II24 / II26

页数：3